Glimser 2 Tablet PR is a combination oral antidiabetic medication containing Glimepiride 2 mg and Metformin 500 mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class agent, enhances pancreatic insulin secretion, thereby improving glycemic control. Metformin, a biguanide, primarily acts by reducing hepatic glucose production and increasing peripheral insulin sensitivity. The combined action of these agents provides a complementary mechanism to effectively lower blood glucose levels in patients inadequately controlled by diet and exercise alone. Glimser 2 Tablet PR is typically prescribed as part of a comprehensive diabetes management plan, including lifestyle modifications such as diet and physical activity. It is important to initiate therapy under medical supervision with appropriate dose titration based on glycemic response and tolerance. Common adverse effects may include gastrointestinal disturbances, hypoglycemia, and rarely, lactic acidosis associated with Metformin. Regular monitoring of blood glucose, renal function, and liver enzymes is recommended during treatment. This medication is contraindicated in patients with type 1 diabetes, diabetic ketoacidosis, severe renal or hepatic impairment, and hypersensitivity to its components. Glimser 2 Tablet PR offers an effective therapeutic option for improved glycemic control in type 2 diabetes when used as directed by a healthcare professional.